csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when